NCT03178656 is a Phase 4 clinical trial of Sorafenib in Portal Vein Tumor Thrombus, sponsored by Huazhong University of Science and Technology.

Who is sponsoring NCT03178656?

NCT03178656 is sponsored by Huazhong University of Science and Technology.

What drugs are being tested in NCT03178656?

Interventions in NCT03178656: Sorafenib, surgery.

What condition does NCT03178656 study?

NCT03178656 studies Portal Vein Tumor Thrombus.

Is NCT03178656 still recruiting?

NCT03178656 is currently status unknown. Last updated 21 December 2017.

Last reviewed 2017-12-21 · How we verify

NCT03178656

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis

Status unknown Phase 4 Last updated 21 December 2017

What this trial tests

Phase 4 trial testing Sorafenib in Portal Vein Tumor Thrombus in 54 participants. Status unknown.

Timeline

15 December 2016

Primary endpoint
15 April 2018

15 December 2019

Quick facts

Lead sponsor	Huazhong University of Science and Technology
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	54
Start date	15 December 2016
Primary completion	15 April 2018
Estimated completion	15 December 2019
Sites	1 location across China

Drugs / interventions tested

Sorafenib (SORAFENIB) — full drug profile →
surgery

Conditions studied

Portal Vein Tumor Thrombus — all drugs for Portal Vein Tumor Thrombus →

Sponsor

Huazhong University of Science and Technology

Who can join

Adults 20 to 75, any sex, with Portal Vein Tumor Thrombus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to the guidelines recommended, only a few new targeted therapy drugs treatment, such as Sorafenib, is proper. It's 3 year survival rate is only 8% or so. According to our previous study, patients with hepatic carcinoma without portal vein tumor thrombus backbone and the contralateral tumor thrombus applyed tumor excision, along with tumor thrombus, the 3 year survival rate can reach 39.9%, the 5-year survival rate can reach 22.7%, curative effect is obviously better.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sorafenib

Trials testing the same drug.

NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT06474663 — A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabi · Phase 1 · withdrawn
NCT06690697 — Combination of Toripalimab and JS004 Therapy for ccRCC · Phase 2 · recruiting
NCT06177496 — Influence of Sarcopenia in Hepatocellular Carcinoma Patients · unknown
NCT05033522 — Immunotherapy for Advanced Liver Cancer · Phase 2, PHASE3 · suspended

Other recruiting trials for Portal Vein Tumor Thrombus

Currently open trials in the same condition.

NCT07062055 — BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases · Phase 2 · recruiting
NCT06622031 — TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT · NA · recruiting

Other Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
NCT07509866 — Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal · NA · recruiting
NCT07326943 — Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block · NA · recruiting
NCT07229976 — Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03178656 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huazhong University of Science and Technology
Last refreshed: 21 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03178656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing